Rapport Therapeutics’ RAP-219 Achieves 90% Seizure Reduction, Secures $476.8M Funding
Rapport Therapeutics reported Phase 2a follow-up data for RAP-219 showing a 90% median reduction in clinical seizures in weeks 9-12 and extended the drug’s half-life to 22 days. The company ended Q1 2026 with $476.8 million in cash and inked a Greater China development and commercialization license.
1. Phase 2a Seizure Trial Results
In the 8-week follow-up period of its Phase 2a trial in focal onset seizures, RAP-219 delivered an 80% median reduction in long episodes and a 90% median reduction in clinical seizures during weeks 9-12, with continued biomarker response through week 16 and an updated half-life estimate of 22 days.
2. Ongoing and Upcoming Clinical Programs
The Phase 3 program for RAP-219 in focal onset seizures is on track to begin in Q2 2026, an open-label safety trial will report data in H2 2026, and plans include a Phase 3 trial in primary generalized tonic-clonic seizures in H1 2027, alongside expedited topline results for the bipolar mania Phase 2 trial now expected in Q4 2026.
3. Financial Position
Rapport closed Q1 2026 with $476.8 million in cash, cash equivalents and short-term investments, reported a net loss of $19.9 million and generated $20.0 million in collaboration revenue, supporting operations into the second half of 2029.
4. Strategic Collaboration
A license agreement with Tenacia Biotechnology grants development and commercialization rights for RAP-219 in Greater China across seizure and bipolar indications, with upfront and milestone payments accelerating regional expansion.